文献速递淋巴瘤

CLL12试验:伊布替尼对比安慰剂治疗初治早期慢性淋巴细胞白血病

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
PubMed 文献 · Blood · 2022-01-01

CLL12是一项3期双盲安慰剂对照试验,将进展风险增高的无症状初治Binet A期慢性淋巴细胞白血病患者按1:1随机分配至伊布替尼420 mg每日一次组(n=182)或安慰剂组(n=181)。中位随访31个月时,伊布替尼组无事件生存显著优于安慰剂组(中位未达到 vs 47.8个月;HR=0.25;95%CI=0.14-0.43,P<.0001),总毒性未增加,但结果不足以改变当前「观察等待」标准。

要点

  • 伊布替尼组无事件生存显著优于安慰剂组(中位未达到 vs 47.8个月;HR=0.25;95%CI=0.14-0.43,P<.0001)。
  • 伊布替尼未增加总体毒性,不良事件发生率和严重程度与安慰剂相似。
  • 结果不支持改变当前「观察等待」标准。

核心结论

  • 伊布替尼在进展风险增高的早期慢性淋巴细胞白血病患者中证实有效,但结果不足以改变当前「观察等待」标准。

研究设计与样本

  • 3期双盲安慰剂对照试验,将进展风险增高的无症状初治Binet A期慢性淋巴细胞白血病患者按1:1随机分配至伊布替尼420 mg每日一次组(n=182)或安慰剂组(n=181)。

主要发现

  • 中位随访31个月时,伊布替尼组无事件生存显著优于安慰剂组(中位未达到 vs 47.8个月;HR=0.25;95%CI=0.14-0.43,P<.0001)。
  • 与安慰剂相比,伊布替尼未增加总体毒性,不良事件发生率和严重程度相似。
  • 伊布替尼组最常见的严重不良事件为心房颤动、肺炎和皮疹;安慰剂组为基底细胞癌、肺炎和心肌梗死。
  • 伊布替尼相关出血风险为33.5%,通过研究方案修订禁止使用口服抗凝药及避免CYP3A4药物相互作用而降低。

临床怎么用

  • 原文结论指出,结果不足以改变当前「观察等待」标准。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Observation is the current standard of care for patients with early-stage asymptomatic chronic lymphocytic leukemia (CLL), as chemotherapy-based interventions have failed to prolong survival. We hypothesized that early intervention with ibrutinib would be well tolerated and lead to superior disease control in a subgroup of early-stage patients with CLL. The phase 3, double-blind, placebo-controlled CLL12 trial randomly assigned asymptomatic, treatment-naïve Binet stage A CLL patients at increased risk of progression in a 1:1 ratio to receive ibrutinib (n = 182) or placebo (n = 181) at a dose of 420 mg daily. At a median follow-up of 31 months, the study met its primary endpoint by significantly improving event-free survival in the ibrutinib group (median, not reached vs 47.8 months; hazard ratio = 0.25; 95% confidence interval = 0.14-0.43, P < .0001). Compared with placebo, ibrutinib did not increase overall toxicity, yielding similar incidence and severity of adverse events (AEs). The most common serious AEs were atrial fibrillation, pneumonia, and rash in the ibrutinib group, and basal cell carcinoma, pneumonia, and myocardial infarction in the placebo group. Ibrutinib-associated risk for bleeding (33.5%) was decreased by prohibiting the use of oral anticoagulants through an amendment of the study protocol and by avoiding CYP3A4 drug-drug interactions. Ibrutinib confirms efficacy in CLL patients at an early stage with an increased risk of progression. However, the results do not justify changing the current standard of "watch and wait." This trial was registered at www.clinicaltrials.gov as #NCT02863718.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Langerbeins P, Zhang C, Robrecht S, et al. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Blood. 2022. PMID: 34758069. doi:10.1182/blood.2021010845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。